Diamyd reports successes in Q4

Diamyd, who is in the the final phase of FDA approval for a type 1 diabetes vaccine, reported trials were still going well. A followup from their phase II study four years ago shows that their vaccine is effective and safe so far! This is great news. Keep your eye on Diamyd to emerge with a FDA-approved diabetes vaccine!

A four-year follow-up of type 1 diabetes patients who were part of the Company's Phase II study shows a clear positive trend. In February Diamyd Medical received approval from the Swedish Medical Products Agency to follow up the children and adolescents with type 1 diabetes who were part of the Company's previously reported Phase II study with the Diamyd(R) diabetes vaccine that began in 2005. An initial analysis of the new data shows that four years after treatment, those patients who received the Diamyd(R)-vaccine and who had recently developed the disease when the study began still have a better diabetes status than corresponding patients who received a placebo. The safety data also continues to look promising, without any serious side effects associated with the treatment.

Link: Press Release - Diamyd reports successes in Q4